Revista de psiquiatria y salud mental
January 1, 2023
Neus Miquel-Giner, Muriel Vicent-Gil, Ignacio Martínez-zalacaín et al.
4 citations
About 40-50% of patients with obsessive-compulsive disorder (OCD) continue to experience obsessions and compulsions after first-line treatments. Mindfulness-based cognitive therapy (MBCT) is proposed as an augmentation strategy to help patients decentre from distressful thoughts, potentially increasing non-reactivity and reducing compulsions. This randomized clinical trial of 60 OCD patients who did not respond to first-line treatments will compare an MBCT program (10 weekly 120-minute sessions) with treatment as usual. The primary outcome is change in OCD severity, measured by clinician and self-reported assessments. Comprehensive evaluations will include comorbid clinical variables, neuropsychological functioning, thought content, and structural and functional neuroimaging at baseline and post-intervention. This is the first RCT in this population to examine clinical, neuropsychological, and neuroimaging variables together to identify neural patterns associated with MBCT response.
The journal of ECT
January 29, 2026
Sergi López-rodríguez, Aida De Arriba-Arnau, José Manuel Menchón et al.
1 citation
Combining electroconvulsive therapy (ECT) with intranasal esketamine (ESK) may offer sustained improvement for adults with severe treatment-resistant depression who had only partial benefit from either treatment alone. In four patients aged 50 to 72, the combination reduced depression scores by an average of 58% over 24 weeks, with no relapses. Two patients who added the complementary treatment to partial monotherapy showed symptom reductions of 50% and 37%. Two others who were already responding to maintenance ECT had further improvements of 62% and 83%, allowing ECT sessions to be spaced from weekly to every two to three weeks. Side effects were mild and temporary, including brief dissociation and post-ictal confusion. These findings suggest the combination is feasible and warrants controlled trials.
BMC psychiatry
April 26, 2026
Sergi López-rodríguez, Cinto Segalàs, Eva Real et al.
In eight adults with treatment-resistant obsessive-compulsive disorder and comorbid major depressive disorder, twelve weeks of intranasal esketamine (56-84 mg per session) substantially improved depressive symptoms, with MADRS scores decreasing by 48.8%. Obsessive-compulsive symptoms showed a more modest and heterogeneous reduction, with Y-BOCS scores decreasing by 30.3%. Half of participants achieved depression response, and half met OCD response criteria. Depressive symptoms improved earlier, while OCD symptoms followed a slower and more variable trajectory. These preliminary findings suggest that repeated intranasal esketamine may offer a therapeutic window for this severe subgroup, supporting further controlled studies.